Pfizer has signed an MoU (Memorandum of Understanding) with the UAE-based Friends of Cancer Patients (FOCP) and Emirates Oncology Society.
The MoU reinforces the pharmaceutical company's commitment to advancing oncology care, encouraging early detection, and supporting cancer treatment in the country.
"Cancer is one of the greatest health challenges we collectively face. Therefore, as part of our renewed commitment at Pfizer to Friends of Cancer Patients and Emirates Oncology Society, we want to ensure that we are doing everything we can across the UAE to support cancer patients," said Pfizer Gulf Cluster Lead Lindsey Dietschi.
Thanks to new treatments, UAE patients have been fighting cancer and surviving, especially when detected early, according to Chairperson of FCOP’s Board of Directors Sawsan Jafar.
'The rate of cancer patients is expected to grow two-fold in the Gulf Corporation Council (GCC) countries by 2025 compared to the rest of the world," said Dr. Humaid al-Shamsi, President of Emirates Oncology Society, stressing that their "first and most critical defense against cancer is early detection."
News Source: Emirates News Agency
